Microbix Biosystems Inc. (MBXBF) Stock

About Microbix Biosystems Inc.

Microbix Biosystems Inc. is a life sciences enterprise that invents and markets unique biological and technological innovations designed to improve human health and well-being. Operating across North America, Europe, and other international markets, the company primarily produces essential biological reagents for the diagnostics industry. This includes antigens for immunoassays and its proprietary Quality Assessment and Proficiency (QAP) products. These QAPs are crucial for supporting clinical laboratory proficiency testing, aiding in assay development and validation, and streamlining lab workflows. Furthermore, Microbix leverages its biological knowledge and infrastructure to create other specialized products, such as its DxTM (viral transport medium) for stabilizing patient samples for laboratory analysis, and Kinlytic Urokinase, a biologic drug for treating blood clots. Its QAP offerings are sold to laboratory accreditation organizations, diagnostic firms, and clinical laboratories via a network of regional distributors. Founded in 1988, Microbix Biosystems Inc. is headquartered in Mississauga, Canada.

Microbix Biosystems Inc. is headquartered in CA.

Microbix Biosystems Inc. (MBXBF) stock trades at $0.22 with a market capitalization of $30.25M. The stock is valued at a price-to-earnings (P/E) ratio of -7.44, price-to-book of 1.68, price-to-sales of 2.83. Over the past 52 weeks the stock has ranged between $0.15 and $0.23, and currently trades 4.3% below its 52-week high.

On profitability, Microbix Biosystems Inc. generates a return on equity (ROE) of -21.02%, return on capital employed of -15.80%, an operating margin of -33.32%, a net profit margin of -38.62%.

Official website: microbix.com